Actor Sam Trammell, best known for his role in HBO's "True Blood," dishes about his upcoming projects, "Generation" (produced by Lena Dunham), and "The Tiger Rises."
Actor Sam Trammell, best known for his role in HBO's "True Blood," dishes about his upcoming projects, "Generation" (produced by Lena Dunham), and "The Tiger Rises."
The Herpes Treatment Market will grow by $ 677.02 mn during 2020-2024
A Christmas Carol at the Bridge theatre, starring Simon Russell Beale, inaugurated a spate of openings over the coming fortnight, with a matinee and evening performance the day after lockdown ended. The programme of monologues by Alan Bennett, David Hare and others that the Bridge put on, as one of the few theatres to reopen during the loosening of restrictions, was a lifeline. To see London’s playhouses largely closed for eight months “has been heartbreaking, so it is joyous to be here tonight”, said Kate Vann, there with her husband Martin.
It’s time to party! Ryan Murphy’s Broadway adaptation is plenty of fun
The retailer follows Tesco, Sainsbury's, Asda, Aldi, Morrisons and B&M in agreeing to voluntarily make the payments.
The first coronavirus vaccines could reach Poland in January, the Polish prime minister's top aide said on Friday, as emerging Europe's biggest country prepares to roll out its COVID-19 vaccination programme. Poland has ordered 45 million COVID-19 vaccines, and Prime Minister Mateusz Morawiecki has said the country intended to start vaccinating health workers, security forces and the elderly in February. "Similarly to other countries, it looks like the first batches of vaccine will reach Poland in January, because the approval process will take place in late December and early January," the prime minister's chief of staff Michal Dworczyk told public broadcaster Polskie Radio Program 1.
Edinburgh was woken up this morning by a loud storm as extreme weather struck the Scottish city. Alarmed residents reported hearing "terrifying" bangs that "sounded like bombs going off" as thunder and lightning hit the area in the early hours. Twitter was awash with residents asking what was going on, with police forced to reassure people that the strange noises were just due to the weather.
Land Securities on Friday said there is “strong investor demand” for high quality properties in London as it revealed a £552 million deal to sell office buildings 1 & 2 New Ludgate. The FTSE 100 property giant said it has exchanged contracts to sell its 1.5 acre site next to the Old Bailey, to Singapore-based investment firm Sun Venture. Completion is expected by the end of this month, and the proceeds will be used to pay down debts and will be reinvested into growth opportunities.
This week, Senior Advisor and First Daughter Ivanka Trump was deposed as part of an investigation by the Washington, D.C. attorney general’s office into a misuse of inauguration funds by the Presidential Inauguration Committee (PIC). The attorney general’s office sued the Trump Organization and the PIC in January, alleging that the organisation violated its status as a nonprofit by misusing more than $1 million USD in funds and “grossly overpaying” the Trump Hotel for event space for the 2017 presidential inauguration. On Tuesday, the eldest Trump daughter sat with investigators to try and explain yet another legal line the Trump administration has crossed. According to the lawsuit, the PIC — under the direction of Rick Gates, the former inaugural committee deputy chairman — paid $175,000 USD per day for four days to reserve space at the Trump Hotel. Wolkoff expressed discomfort with that fee, noting that it was nearly twice the market rate, and expressed that concern to both U.S. President Trump and Ivanka in an in-person meeting as well as in a followup email. In addition to Ivanka, the attorney general’s office has subpoenaed records from Tom Barrack, chairman of the inaugural committee, first lady Melania Trump, and Gates. Barrack was deposed November 17 and Stephanie Winston Wolkoff, the inauguration’s event planner will be deposed next week. Despite spending, according to her Twitter, 5+ hours in deposition, Ivanka may not be out of the woods just yet. In her capacity as senior advisor, Ivanka has been in the trenches of the Trump operation for some time now. And although she was spared from similar inquiries in early 2019, Ivanka is no longer off the table when it comes to investigating the Trump administration’s wrongdoings. Now the question remains: Are her crimes enough to land her in jail? “Ms. Trump’s only involvement was connecting the parties and instructing the hotel to charge a ‘fair market rate’, which the hotel did,” Alan Garten, general counsel for the Trump Organization, told CNN. But this is not the first time Ivanka’s name has been mentioned in a lawsuit connected to the dealings of her father’s administration or companies. There are currently two New York state fraud investigations into President Trump and his businesses, which are investigating consulting fees that may have been paid to Ivanka, though she is not the focus of those investigations. Ivanka’s involvement with negotiations for a failed Trump Tower in Moscow was probed as part of the Mueller investigation and in 2019, the FBI looked into her international business dealings. Last year, Ivanka and her brothers were ordered to receive “mandatory training” on the “duties of officers and directors of charities so that they cannot allow the illegal activity they oversaw at the Trump Foundation to take place again” as part of a settlement in a case that led to the closing of the president’s charity, which the New York attorney general called “little more than a checkbook for payments from Mr. Trump or his businesses to nonprofits, regardless of their purpose or legality.” Michael Cohen, the president’s former lawyer who pleaded guilty in 2018 in two separate criminal cases related to his work for the Trump campaign and organisation, told MSNBC last month that he believes Ivanka will go to jail before her father does. “I believe Trump does go to jail and if it’s not Trump, he’ll push one of the kids, probably Don, Jr. before Ivanka . . . definitely, Eric before Ivanka, but Ivanka will go to prison before Donald because that’s just who he is,” Cohen said. Many people in Trump world believe Ivanka may have her own political ambitions after her father leaves office, perhaps eyeing a 2024 presidential run or perhaps even a Congressional seat, but Cohen thinks she would not open herself up to that kind of public scrutiny. “There’s too much potential dirt that she doesn’t want released,” Cohen said, according to the Washington Post. “It’s easy to say, ‘I‘m doing this, I’m doing that,’ but it’s different to put your entire life out there for the media to excoriate you.” The president may know that his daughter has been involved in dealings that could get her in legal trouble, which would explain why there are reports that he is looking into preemptively pardoning his children before leaving office — including Ivanka. While Ivanka has not definitively been connected to any legal wrongdoing, she is closely connected to many other people in Trump’s orbit who have been and it remains to be seen how long her luck will last. Like what you see? How about some more R29 goodness, right here?Ivanka Trump's BFF Tell-All Confirms What We KnowSo...What’s Ivanka Doing Next?Why Is Ivanka Bragging About Voting By Mail?
Michael Reader, 70, killed Marion Price in a drive-by shooting in Earls Barton, Northamptonshire, after being ordered to pay her a £10,000 divorce settlement.
Vaccinations against Covid-19 in France will be free, the French prime minister said Thursday. The three-stage innoculation programme will begin in January for 1 million elderly in retirement homes, February for 14 million high-risk people and spring for the rest of the population. Prime minister Jean Castex said that thanks to orders already made at a European level, "France will have a potential of 200 million doses, which would allow 100 million people to be vaccinated" because the course requires two injections a few weeks apart."The vaccination will be free for all," Castex told a press conference on Thursday. That means everyone in France's social security system.It has set aside €1.5 billion of next year's social security budget to cover the cost. When and how will Covid-19 vaccines become available? The country's vaccination campaign is set to begin in January, but could begin earlier, at the end of December, Castex said, if the vaccine was approved by the European Medicines Agency and French health authorities.The government's vaccine strategy would be presented to parliament this month, Castex said, emphasising that all decisions around it would be transparent.Reassuring the scepticsFrance is one of the world's most vaccine-sceptic nations, with a survey over the weekend showing that only 41 percent of the 66 million population planned to get innoculated, far lower than in the UK or US.The Covid-19 vaccination will be voluntary in France. Castex assured citizens the approved vaccines would be safe."The remarkable mobilisation worldwide has allowed the rapid development of vaccines. However, this timeframe in no way means that we have compromised safety," the prime minister said.Limited New Year gatherings Castex also weighed into a debate around the New Year's Eve celebrations, when gatherings are feared to send infections surging.He said "it seems reasonable to us" to recommend a maximum of six adults at such gatherings, not including children.Castex said the spread of the virus was continuing to slow in France and would soon go below the threshold of 10,000 new infections per day. France recorded more than 80,000 new cases at the peak of the second wave in November.More than 53,000 Covid-related deaths have been recorded in France.(with AFP, Reuters)
Help kids get to sleep the night before the highly anticipated day with one of these
Energy giant SSE today showed how lucrative green energy speculation can be as it sold a stake in the planned Dogger windfarm for £202 million, resulting in a big upgrade to its profit forecasts. SSE has been developing the world’s biggest windfarm 60 miles off the north east coast of England in the North Sea with Norwegian partner Equinor.
WA Museum Boola Bardip denies changes to China display were due to political pressureAfter complaint from consul general, description of Covid-19 as virus ‘originating in China’ was changed and Taiwan included in map of China
Mobo founder Kanya King: 'I’ve been fighting to break down barriers. It's isolating'On hiatus since 2017, the Music of Black Origin awards return next week with black British music stronger than ever – but the industry still unequal. Its founder explains the work that needs to be done
Chess: British online championships can lead to a Hastings centenary chance“Onerous” anti-cheating measures spark debate as leading players are slow to enter
At this time, I would like to turn the conference over to Shane Canestra, SAIC's Vice President of Investor Relations. Good afternoon, and thank you for joining SAIC's third quarter fiscal year 2021 earnings call. My name is Shane Canestra, Vice President of Investor Relations and joining me today to discuss our business and financial results are Nazzic Keene, SAIC's Chief Executive Officer; and Charlie Mathis, our Chief Financial Officer.
DGAP-News: ENDRA Life Sciences Inc. / Key word(s): Alliance04.12.2020 / 09:00 The issuer is solely responsible for the content of this announcement.ENDRA Life Sciences Announces New Clinical Study Partnership with the Centre Hospitalier Universitaire d'Angers, FranceStudy to Bolster Clinical Evidence of Performance of Patented TAEUS Ultrasound Device in NAFLD Patients as Commercialization BeginsANN ARBOR, MI / ACCESSWIRE / December 3, 2020 / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of enhanced ultrasound technologies, today announced that Centre Hospitalier Universitaire d'Angers, France (CHU Angers), a world-renowned healthcare institution, is partnering with ENDRA for a clinical study of ENDRA's Thermo Acoustic Enhanced UltraSound (TAEUS(TM)) device for assessing Non-Alcoholic Fatty Liver Disease (NAFLD)."We are thrilled that CHU Angers, a renowned French clinical and teaching institution, is evaluating TAEUS as a tool to characterize NAFLD, a condition that impacts more than 1 billion people globally," said ENDRA Life Sciences Chief Commercial Officer Renaud Maloberti. "It's an honor for ENDRA to garner the clinical interest of this leading research institution. We look forward to building our relationship with CHU Angers as we begin commercializing TAEUS in Europe."This is the second clinical research partnership for ENDRA in Europe and the fifth globally. It is a natural progression from the feasibility study conducted by the Robarts Research Institute in Canada, and the first evaluation site that was deployed earlier this month at Rocky Vista University in the United States. The data from the CHU Angers study, along with other ongoing or to-be-initiated studies, will be used to bolster the clinical evidence and further establish the clinical utility of the TAEUS ultrasound device in patients with NAFLD, as commercialization begins. The study will be led by Pr. Christophe Aube, MD, PUPH, Chair of the Radiology department in close association with Pr. Jerome Boursier, MD, PUPH, Chair of the Hepatology department."NAFLD and NASH are rapidly rising among the population and the options to assess and monitor liver fat in NAFLD patients, namely MRI and liver biopsy, are difficult to integrate into routine clinical practice. Clinicians need to have access to more practical tools to help manage patients with this chronic condition," said Pr. Aube. "We are looking forward to conducting this evaluation of TAEUS in our patients with NAFLD, and to better understanding the potential clinical utility of ENDRA's TAEUS technology as it compares to MRI," added Pr. Boursier.The goals of the CHU Angers study include: Comparing ENDRA's commercial design TAEUS liver device against a baseline measure of liver fat as determined by the current standard of care, MRI-PDFF (magnetic resonance imaging proton density fat fraction). Scanning a target of 75 fatty liver patients to contribute additional diversity and volume of patient data. Providing ENDRA with ongoing clinical feedback on product design and clinical performance. Assisting with the establishment of the clinical value proposition of the TAEUS system in NAFLD to support ongoing commercialization efforts.About Non-Alcoholic Fatty Liver Disease (NAFLD)NAFLD is a condition closely associated with obesity, diabetes, hepatitis C and certain genetic predispositions in which fat accumulates in the liver. NAFLD affects over 1 billion people globally and is estimated to cost the U.S healthcare system over $100 billion annually. NAFLD is often asymptomatic and if left untreated, NAFLD can progress to inflammation (NASH), tissue scarring (fibrosis), cell death (cirrhosis) and liver cancer. By 2025, NAFLD is forecast to be the greatest root cause of liver transplants. The only tools currently available for diagnosing and monitoring NAFLD are impractical: expensive Magnetic Resonance Imaging (MRI) or an invasive surgical biopsy.About the Centre Hospitalier Universitaire d'Angers (CHU Angers)The University Hospital of Angers is a reference healthcare hub with the threefold mission of healthcare, teaching and research. As both a local hospital and a national center of expertise, the hospital reconciles innovation with community service on a daily basis. As one of the region's largest healthcare providers treating more than 190,000 patients a year and with 1,357 beds and places, quality is a key consideration for Angers University Hospital, especially when it comes to patient care.The Hepatology axis, including NAFLD and hepatic fibrosis, is one of the six major research priorities of the University Hospital of Angers. It brings together a multidisciplinary team of academic physicians specialized in digestive diseases, and is supported by four transversal functional units: Histology Department; Radiology Department; Biochemistry & Molecular Biology; and a dedicated Clinical Research Unit. The Clinical Research Unit of the Hepato-Gastroenterology Department has qualified engineers and technicians in charge of the day-to-day clinical research work (management of data entry operators, organization of samples logistics and specific biological analysis, etc.). This unit is highly experienced in clinical research with around 103 academic and industrials studies currently ongoing. The Hepato-Gastroenterology Department is one of the leading centers in France for inclusion in NAFLD and NASH clinical trials.About ENDRA Life Sciences Inc.ENDRA Life Sciences Inc. is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS(TM)), a ground-breaking technology that mirrors some applications similar to CT or MRI, but at 50X lower cost and at the point of patient care. TAEUS is designed to work in concert with one million ultrasound systems in global use today. TAEUS is initially focused on the measurement of fat in the liver, as a means to assess and monitor NAFLD and NASH, chronic liver conditions that affect over 1 billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.www.endrainc.com.Forward-Looking StatementsAll statements in this release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "goal," "estimate," "anticipate" or other comparable terms. Examples of forward-looking statements include, among others, estimates of the timing of future events and achievements, such as the expectations regarding milestones and future sales; the timing of; making our 510(k) submission with the FDA and commercializing the TAEUS device; and expectations concerning ENDRA's business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including, among others, our ability to develop a commercially feasible technology; receipt of necessary regulatory approvals; the impact of COVID-19 on our business plans; our ability to find and maintain development partners, market acceptance of our technology, the amount and nature of competition in our industry; our ability to protect our intellectual property; and the other risks and uncertainties described in ENDRA's filings with the Securities and Exchange Commission. The forward-looking statements made in this release speak only as of the date of this release, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.Company Contact:David WellsChief Financial Officer(734) firstname.lastname@example.orgInvestor Relations Contact:Kim Sutton GolodetzLHA Investor Relations(212) email@example.comSOURCE: ENDRA Life Sciences Inc.04.12.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
DGAP-News: Mutares SE & Co. KGaA / Key word(s): Disposal/Investment04.12.2020 / 09:00 The issuer is solely responsible for the content of this announcement.Mutares SE & Co. KGaA: Balcke-Dürr Group sells Balcke-Dürr Rothemühle to Howden after a successful turnaround - Final divestment of Rothemühle business following the sale of activities in Poland in spring 2020- Double-digit Return on invested Capital for Balcke-Dürr Group- Successfully aligned work with Management on the entire exit process Munich, 04 December 2020 - Balcke-Dürr, a holding of Mutares SE & Co. KGaA (ISIN: DE000A2NB650), has sold Balcke-Dürr Rothemühle to Howden Group after a successful reorganization and carve out. Balcke-Dürr Rothemühle is an integrated service, engineering and original equipment provider to the flue gas path segment of power and process plants. The company was established in 1936 and is a leading global provider of Air Preheaters, Gas-Gas Heaters and related heat recovery equipment. The transaction is expected to close in Q1 2021 and is subject to regulatory approval.Mutares acquired the business as part of the acquisition of Balcke-Dürr Group in November 2016 from SPX Corporation based in Charlotte, USA. Focal points of the restructuring process have been footprint adjustments, capacity optimization as well as a focus on service-related business. The unit was carved out in 2019 with the aim of being sold as an independent entity. In 2019 the company generated a turnover of EUR 23.0 million with a team of 55 employees. The entire management team will remain on board.Johannes Laumann, CIO of Mutares, comments: "This sale highlights our core competence of refocusing businesses to their fundamental expertise, in this case the profitable service business. Due to management empowerment and successful repositioning as an independent entity we have revitalized the Rothemühle brand and established it in the market. We believe Howden is the ideal new owner to lead the company into the next phase of internationalization, both in terms of products and technology."Ross B Shuster, CEO of Howden, said: "Rothemühle's service and product offerings support our environmental technology efforts by reducing emissions and improving plant operating efficiencies in their critical processes. This acquisition will extend Howden's presence in the German market, whilst giving the Company access to Howden's global network. We are pleased to welcome the Rothemühle team to Howden." About Howden GroupHowden is a leading global provider of mission critical air and gas handling products. The company enables their customers' vital processes which advance a more sustainable world. Based in Glasgow, Scotland, Howden has over 60 years heritage as a world-class application engineering and manufacturing company with a presence in 36 countries. Howden manufactures highly engineered fans, compressors, heat exchangers, steam turbines, and other air and gas handling equipment, and provides service and support to customers around the world in highly diversified end-markets and geographies. Company profile Mutares SE & Co. KGaAMutares SE & Co. KGaA, Munich (www.mutares.de), as a listed private equity holding company with offices in Munich (HQ), Frankfurt, Helsinki, London, Madrid, Milan, Paris, Stockholm and Vienna, acquires medium-sized companies and parts of larger groups with headquarters in Europe that show a clear potential for operational improvement and are sold again after undergoing a repositioning and stabilization process. Mutares actively supports and develops its portfolio companies with its own investment and consulting teams as well as through acquisitions of strategic add-ons. With for aim a ROIC (Return on Invested Capital) of 7 to 10 times on the total investment with a focus on sustainable growth of the portfolio companies. In 2020, Mutares SE & Co. KGaA expects generated consolidated revenues of approx. EUR 1.8 billion employing more than 15,000 people worldwide. Based on this, consolidated revenues are expected to increase to approximately EUR 3.0 billion by 2023. Mutares is strongly committed to a sustainable dividend policy consisting of a base dividend and a performance dividend, which has been stable above 10% yield in the past years. The shares of Mutares SE & Co. KGaA are listed on the Frankfurt Stock Exchange under the ticker symbol "MUX" (ISIN: DE000A2NB650).For further information please contact us:Mutares SE & Co. KGaAInvestor RelationsPhone +49 89 9292 7760email: firstname.lastname@example.orgPress contactCROSS ALLIANCE communication GmbHSusan HoffmeisterPhone +49 89 125 09 0333Email: email@example.com 04.12.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: Mutares SE & Co. KGaA Arnulfstr.19 80335 Munich Germany Phone: +49 (0)89-9292 776-0 Fax: +49 (0)89-9292 776-22 E-mail: firstname.lastname@example.org Internet: www.mutares.de ISIN: DE000A2NB650 WKN: A2NB65 Indices: Scale 30 Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Munich, Stuttgart, Tradegate Exchange EQS News ID: 1152799 End of News DGAP News Service
DGAP-News: APEIRON Biologics AG / Key word(s): Study04.12.2020 / 09:00 The issuer is solely responsible for the content of this announcement.APEIRON Biologics: Patient recruitment completed in Phase II COVID-19 Clinical Trial of APN01- Results of the double-blind, placebo-controlled trial expected in Q1 2021- Preparations for rolling Marketing Authorization Application in Europe commenced- Trial results to confirm unique triple mode of action to prevent infection, organ injury and inflammation.Vienna, Austria, 04 December 2020: APEIRON Biologics AG today announced that patient recruitment of its ongoing Phase II clinical trial with APN01 to treat COVID-19 was completed. The results of the international, multicenter, double-blind, randomized and placebo-controlled trial are expected in Q1 2021.APN01 (alunacedase alfa) is the recombinant form of the human angiotensin-converting enzyme 2 (rhACE2) with a unique triple mode of action: APN01 has the potential to prevent cells from infection with the SARS-CoV-2 virus, reduce injury to multiple organs and additionally to treat the inflammatory reactions in the lungs caused by COVID-19. The specific targeting of SARS-CoV-2 by APN01 was recently confirmed by preclinical results published in the peer reviewed publication CELL.The ongoing Phase II trial compares APN01 to placebo with approximately 100 patients per treatment arm in severely infected COVID-19 patients at multiple sites in Germany, Austria, Denmark, UK and Russia. The primary objective of the trial is to assess the clinical efficacy and safety of APN01 in severe COVID-19 patients using, among other criteria, the need for invasive mechanical ventilation. Secondary objectives include the evaluation of measurable biological biomarker changes following treatment with APN01."APN01 is one of the most advanced COVID-19 drug candidates and the only clinical stage treatment specifically targeting SARS-CoV-2. We have seen clear results in preclinical studies and named patient use confirming the mode of action and clinical benefit of APN01 in COVID-19 patients and feel encouraged to confirm efficacy with this clinical phase II trial," said Peter Llewellyn-Davies, Chief Executive Officer of APEIRON Biologics AG. "Currently, we are defining with the European Medicines Agency (EMA) a potential rolling Marketing Authorization Application (MAA) submission to make this drug candidate available for severely suffering patients as fast as possible, subject to positive clinical results."About APN01 / alunacedase alfa (soluble ACE2)APN01 is a recombinant human Angiotensin Converting Enzyme 2 (rhACE2). Before clinical development in COVID-19 started in April 2020, APN01 successfully completed several clinical trials in severe respiratory diseases like acute lung injury (ALI), acute respiratory distress syndrome (ARDS) and pulmonary arterial hypertension (PAH). Lung injuries caused by ARDS are one of the major sources of severe COVID-19.In these clinical trials, safety and tolerability of APN01 were demonstrated. A peer reviewed publication The Lancet Respiratory Medicine recently published encouraging safety and efficacy data for APN01 for the treatment of COVID-19 in a Case Study with named patient use.Unique triple Mode of Action- Prevent infection / virus neutralization: APN01 is the soluble form of ACE2, the receptor for entry of SARS-CoV2 into the cell. Binding of APN01 to viral spike protein prevents binding of the virus to cell surface receptors and thereby prevents infection of cells.- Prevent organ injury / reduction of disease mediated organ pathology: APN01 shifts the Renin-Angiotensin-System (RAS) towards repair and reduction of injuries to blood vessels and organs including the lungs, kidneys or the heart.- Control inflammation: APN01 reduces the release of pro-inflammatory cytokines and chemokines which play an important role in lung injury and cytokine storm, thereby reducing the uncontrolled inflammation triggered by SARS-COV-2.About APEIRON Biologics AGAPEIRON Biologics is a privately held European biotech company based in Vienna, Austria, focused on the discovery and development of treatments for respiratory diseases and novel cancer immunotherapies.APN01 (rhsACE2, alunacedase alfa), a soluble recombinant version of the SARS-CoV-2 cell entry receptor ACE2, has a unique triple mode of action to treat COVID-19 and is undergoing a double blind, placebo-controlled Phase II trial in Europe and Russia.APEIRON received EU marketing approval for APN311 (Dinutuximab beta, Qarziba(R)) in 2017 for the treatment of pediatric neuroblastoma patients and out-licensed global, exclusive rights for this product to EUSA Pharma Ltd.APN401's proprietary process brings in a paradigm change in cancer treatment to fight hematological and solid tumors. The clinical program is a first-in-class ambulatory autologous cellular therapy to strengthen immune reactivity via an intracellular master checkpoint inhibitor, Cbl-b.APEIRON Biologics' projects and technologies are based on a strong patent portfolio and partnerships with leading pharmaceutical companies and academic institutions.Further information at www.apeiron-biologics.com.For further information please contact:APEIRON Biologics AGPeter Llewellyn-DaviesCEOEmail: email@example.comMedia and Investor RelationsMC Services AGJulia HofmannT +49 89 210 228 0Email: firstname.lastname@example.orgFORWARD LOOKING STATEMENTS Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of APEIRON Biologics as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.04.12.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Cashmere, sleeveless, psychedelic and all the best and biggest knitwear trends right now